Standing Order
All companies

Biotech

Tempus AI, Inc.

TEMNASDAQpure-play
Market cap$9.6B
Conviction4/ 5
HQChicago, Illinois, USA
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$54.04

-14.9%

Thesis

Tempus AI builds a multimodal clinical and molecular data platform spanning diagnostics, genomic sequencing, and data licensing. Its scaled real-world datasets support both precision diagnostics and AI-enabled drug discovery partnerships.

Catalysts

  • Genomics and diagnostics testing volume growth
  • Data-licensing and pharma partnership expansion
  • Margin progression as the platform scales

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 18
    DealSEC

    8-K filed with items 1.01 and 9.01 disclosing entry into material definitive agreement.

  • Nov 2
    Financial resultsSEC

    Tempus AI files 8-K (items 2.02,7.01,9.01) reporting results of operations and financial condition.

  • Oct 23
    OtherSEC

    Filed 8-K item 8.01 other events disclosure.

  • Oct 21
    Securities offeringSEC

    Tempus AI filed Form 424B3 prospectus supplement with the SEC on 2026-10-21.

  • Oct 20
    M&ASEC

    Amended S-4 filing for securities issued in business combination.

  • Oct 2
    M&ASEC

    S-4/A amendment to registration statement for proposed business combination filed.

  • Sep 15
    M&ASEC

    SEC Form 425 filing related to business combination.

  • Aug 31
    M&ASEC

    S-4 registration statement filed for merger or acquisition transaction.

Not financial advice — research and opinion only. Disclosures